Biocon opens book for Syngene IPO

Indian pharma company spins off contract research arm, hoping markets will regain a solid footing after Monday's sharp fall.
Markets in need of careful handling
Markets in need of careful handling

Indian pharma company Biocon launched a Rs5.28 billion to Rs5.5 billion $82.2 million to $85.7 million initial public offering in its clinical research arm Syngene International on Monday.

The deal had seemed well-timed, taking advantage of a stock market rally, which began in mid-June. The company will now be hoping Monday's sharp fall does not presage a new downswing.

The Sensex suffered its biggest one-day drop in two months yesterday, closing down 1.96% as it took its cue from China's 8.5% slide. Over the past three trading days it has lost 3.6%.

Biocon is looking to divest an 11% stake in the Bengaluru-based group...

¬ Haymarket Media Limited. All rights reserved.

FinanceAsia has updated its subscription model.

Registered readers now have the opportunity to read 5 articles from our award-winning website for free.

To obtain unlimited access to our award-winning exclusive news and analysis, we offer subscription packages, including single user, team subscription (2-5 users), or office-wide licences.

To help you and your colleagues access our proprietary content, please contact us at subscriptions@financeasia.com, or +(852) 2122 5222

Article limit is reached.

Hello! You have used up all of your free articles on FinanceAsia.

To obtain unlimited access to our award-winning exclusive news and analysis, we offer subscription packages, including single user, team subscription (2-5 users), or office-wide licences. To help you and your colleagues access our proprietary content, please contact us at subscriptions@financeasia.com, or +(852) 2122 5222